RT info:eu-repo/semantics/article
T1 The Incorporation of etanercept into a porous tri-layer scaffold for restoring and repairing cartilage tissue
A1 Campos, Yaima
A1 Fuentes, Gastón
A1 Almirall, Amisel
A1 Que, Ivo
A1 Schomann, Timo
A1 Chung, Chih Kit
A1 Jorquera Cordero, Carla
A1 Quintanilla Sierra, Luis
A1 Rodríguez Cabello, José Carlos
A1 Chan, Alan
A1 Cruz, Luis
K1 Osteoarthritis
K1 Osteoartritis
K1 Tissue engineering
K1 Ingeniería de tejidos
K1 Etanercept
K1 Cartilage - Implants
K1 Cartílago - Implantes
AB Cartilage diseases currently affect a high percentage of the world’s population. Almostall of these diseases, such as osteoarthritis (OA), cause inflammation of this soft tissue. However,this could be controlled with biomaterials that act as an anti-inflammatory delivery system, capableof dosing these drugs over time in a specific area. The objective of this study was to incorporateetanercept (ETA) into porous three-layer scaffolds to decrease the inflammatory process in this softtissue. ETA is a blocker of pro-inflammatory cytokines, such as tumour necrosis factor alpha (TNF-α)and interleukin 6 (IL-6). For this reason, the scaffold was built based on natural polymers, includingchitosan and type I collagen. The scaffold was grafted next to subchondral bone using hydroxyapatiteas filler. One of the biomaterials obtained was also crosslinked to compare its mechanical propertieswith the non-treated one. Both samples’ physicochemical properties were studied with SEM, microCT and photoacoustic imaging, and their rheological properties were also compared. The cell viabilityand proliferation of the human chondrocyte C28/I2 cell line were studied in vitro. An in vitro andin vivo controlled release study was evaluated in both specimens. The ETA anti-inflammatory effectwas also studied by in vitro TNF-α and IL-6 production. The crosslinked and non-treated scaffoldshad rheological properties suitable for this application. They were non-cytotoxic and favoured thein vitro growth of chondrocytes. The in vitro and in vivo ETA release showed desirable results for adrug delivery system. The TNF-α and IL-6 production assay showed that this drug was effectiveas an anti-inflammatory agent. In an in vivo OA mice model, safranin-O and fast green stainingwas carried out. The OA cartilage tissue improved when the scaffold with ETA was grafted in thedamaged area. These results demonstrate that this type of biomaterial has high potential for clinicalapplications in tissue engineering and as a controlled drug delivery system in OA articular cartilage.
PB MDPI
SN 1999-4923
YR 2022
FD 2022
LK https://uvadoc.uva.es/handle/10324/51954
UL https://uvadoc.uva.es/handle/10324/51954
LA eng
NO Pharmaceutics, 2022, vol. 14, n. 2, 282
NO Producción Científica
DS UVaDOC
RD 24-dic-2024